Brokerages expect that Voyager Therapeutics Inc (NASDAQ:VYGR) will announce $2.90 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Voyager Therapeutics’ earnings. The highest sales estimate is $5.00 million and the lowest is $2.00 million. Voyager Therapeutics posted sales of $6.35 million in the same quarter last year, which would indicate a negative year over year growth rate of 54.3%. The firm is scheduled to report its next earnings report on Wednesday, March 13th.
According to Zacks, analysts expect that Voyager Therapeutics will report full year sales of $8.86 million for the current financial year, with estimates ranging from $7.61 million to $11.15 million. For the next fiscal year, analysts anticipate that the firm will post sales of $23.08 million, with estimates ranging from $8.00 million to $68.00 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Voyager Therapeutics.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.63) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.15. Voyager Therapeutics had a negative net margin of 648.40% and a negative return on equity of 81.63%. The business had revenue of $2.09 million for the quarter, compared to the consensus estimate of $3.02 million.
VYGR opened at $9.62 on Friday. Voyager Therapeutics has a 1-year low of $8.30 and a 1-year high of $31.91. The company has a market capitalization of $308.31 million, a price-to-earnings ratio of -3.64 and a beta of 2.73.
Hedge funds have recently made changes to their positions in the company. BB Biotech AG increased its holdings in Voyager Therapeutics by 11.5% in the 3rd quarter. BB Biotech AG now owns 2,822,641 shares of the company’s stock valued at $53,404,000 after acquiring an additional 290,000 shares during the last quarter. BlackRock Inc. increased its holdings in Voyager Therapeutics by 1.0% in the 3rd quarter. BlackRock Inc. now owns 1,863,766 shares of the company’s stock valued at $35,262,000 after acquiring an additional 18,060 shares during the last quarter. Vanguard Group Inc. increased its holdings in Voyager Therapeutics by 10.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after acquiring an additional 113,442 shares during the last quarter. Vanguard Group Inc increased its holdings in Voyager Therapeutics by 10.5% in the 3rd quarter. Vanguard Group Inc now owns 1,196,594 shares of the company’s stock valued at $22,640,000 after acquiring an additional 113,442 shares during the last quarter. Finally, Wells Fargo & Company MN increased its holdings in Voyager Therapeutics by 18.6% in the 3rd quarter. Wells Fargo & Company MN now owns 534,087 shares of the company’s stock valued at $10,105,000 after acquiring an additional 83,607 shares during the last quarter. Hedge funds and other institutional investors own 88.57% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Read More: Cost of Capital Explained
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.